Tao Hiroyuki, Shien Kazuhiko, Soh Junichi, Matsuda Eisuke, Toyooka Shinichi, Okabe Kazunori, Miyoshi Shinichiro
Division of Thoracic Surgery, NHO Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan.
Ann Thorac Cardiovasc Surg. 2014;20(6):980-6. doi: 10.5761/atcs.oa.13-00237. Epub 2014 Feb 28.
To examine the relationship between the density of tumor-infiltrating T cell subpopulations and the pathological response to induction chemoradiotherapy (CRT) in patients with locally advanced NSCLC, and to assess the impact of T cell density on patient prognosis.
A total of 64 patients with c-stages IIA-IIIB NSCLC who underwent induction CRT followed by R0 surgery were enrolled. Tumor-infiltrating T cells expressing either FOXP3 or CD8 were detected by immunohistochemical staining.
Mean numbers of tumor-infiltrating FOXP3+ T cells were 39.9 for patients with minor pathological responses (n = 9), 18.4 for those with major pathological responses (n = 25), and 12.9 for those with complete pathological responses (n = 30; P <0.001). The number of CD8+ T cells was not associated with pathological responses. Patients with lower FOXP3+ T cell densities showed better survival, although the difference was not statistically significant.
Our study demonstrated that the density of tumor-infiltrating FOXP3+ T cells indicated the degree of response for induction CRT and prognosis in patients treated with trimodality therapy for locally advanced NSCLC, suggesting that FOXP3+ T cells may be target for adjunct immunotherapy.
探讨局部晚期非小细胞肺癌(NSCLC)患者肿瘤浸润性T细胞亚群密度与诱导放化疗(CRT)病理反应之间的关系,并评估T细胞密度对患者预后的影响。
共纳入64例c期IIA-IIIB期NSCLC患者,这些患者先接受诱导CRT,然后接受R0手术。通过免疫组织化学染色检测表达FOXP3或CD8的肿瘤浸润性T细胞。
病理反应轻微的患者(n = 9)肿瘤浸润性FOXP3 + T细胞的平均数量为39.9,病理反应主要的患者(n = 25)为18.4,病理反应完全的患者(n = 30)为12.9;P <0.001。CD8 + T细胞数量与病理反应无关。FOXP3 + T细胞密度较低的患者生存率较好,尽管差异无统计学意义。
我们的研究表明,肿瘤浸润性FOXP3 + T细胞密度表明局部晚期NSCLC接受三联疗法治疗患者的诱导CRT反应程度和预后,提示FOXP3 + T细胞可能是辅助免疫治疗的靶点。